Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction-Reference-Cited by-同舟云学术

Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction

Published:2020-10-13 Issue:4 Volume:61 Page:515-521
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Dashwood Alexander¹²³^ORCID,Vale Cassandra¹,Laher Shaaheen¹,Chui Fiona¹,Hay Karen⁴,Wong Yee Weng¹²

Affiliation:

1. Heart Lung Institute The Prince Charles Hospital Chermside Queensland Australia

2. Faculty of Medicine and Cardio‐Vascular Molecular & Therapeutics Translational Research Group University of Queensland Australia

3. Griffith University Southport Queensland Australia

4. QIMR Berghofer Medical Research Institute Brisbane Queensland Australia

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1754

Reference22 articles.

1. Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up

2. Iron deficiency in chronic heart failure: An international pooled analysis

3. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency

4. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial;Lewis GD;JAMA,2017

5. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Iron Deficiency in Heart Failure;JACC: Heart Failure;2024-07

2. Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART‐FID;European Journal of Heart Failure;2024-06-19

3. Hypophosphorémie après traitement par fer injectable chez l’adulte : comparaison entre le carboxymaltose ferrique et l’hydroxyde ferrique-saccharose;Annales Pharmaceutiques Françaises;2023-09

4. Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials;ESC Heart Failure;2023-02

5. Increases in Fibroblast Growth Factor 23 During Treatment With Ferric Carboxymaltose: Potential Adverse Effects on the Heart and Kidneys;Journal of Cardiac Failure;2023-02